DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 16.09.2019 | 09:00

DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

DGAP-News: DiaMonTech GmbH / Key word(s): Alliance

16.09.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

Berlin, 16 September 2019 - Germany's pharmacists want to ease life for millions of diabetics by offering them pain-free blood glucose monitoring without taking blood as soon as possible. The Deutscher Apothekerverband e. V. (DAV; German Association of Pharmacists) and DiaMonTech GmbH, a young and innovative medical technology company, intend a strategic cooperation to significantly improve the care of diabetes patients and to take an innovative step into the future.

"The Deutscher Apothekerverband is an important partner for us as the umbrella organization with more than 19,000 pharmacies in Germany. The signing of the Letter of Intent confirms the mutual will to cooperate in a trusting and productive manner. Diabetes patients need personal care and access to the latest technology. They should be able to get both from the local pharmacy." says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The DAV and DiaMonTech are initially striving to carry out practical tests of the already CE-certified "DMT Base" in selected pharmacies. The "DMT Base" is currently optimized for use in professional environments (e.g. diabetes centers). The patient places his finger on a sensor field for a few seconds and the blood sugar is shown categorized on a display. The blood sugar level can be measured precisely and painlessly without a drop of blood. DiaMonTech thus offers a solution for diabetes patients worldwide that offers them the opportunity to significantly improve their quality of life.

The smaller "DMT Pocket" is currently in development with market launch expected by the end of 2020. This device is supposed to have the size of a smartphone and could therefore become a constant accompaniment for diabetes patients. In Germany alone, around 7.2 million people are currently affected.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



16.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit Financial.de verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen

14. Juli 2020, 16:38

Aktuelle Research-Studie

Original-Research: German Real Estate Capital S.A. (von GBC AG): Management Interview German Real Estate Capital S.A.

14. Juli 2020